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1. Introduction
  Uterine cervical cancer is the most common gynecological 
malignancy among women in China and the second most 
common cancer world-wide[1]. Diagnosis of in situ and 
early invasive cervical carcinoma is difficult due to lack of 
symptoms; as a result, 70% of patients diagnosed are already 
at advanced stages[1]. Standard therapeutic modalities for 
advanced cancer include surgical resection, chemotherapy 
and radiotherapy, but have limited value. 
  The biogenesis of cervical cancer is thought to be a 
continuous and complicated process starting from dysplasia 
to in situ cancer or to invasive cancer. Human papilloma 
virus (HPV) is a major risk factor for cervical cancer[1,2]. 
Despite this clear etiology, the molecular mechanism 
underlying cervical cancer development is still unclear.
  Signal transducers and activators of transcription (STATs) 
proteins are transcription factors that regulate a variety 
of cellular events including differentiation, proliferation, 
cell survival and apoptosis[3,4]. Latent in the cytoplasm, 
STATs are activated and enter the nucleus upon cytokine, 
growth factor, and hormone stimulation[3,4]. Abnormal 
levels and pleiotropic effects of STATs contribute to tumor 
pathogenesis[5-9]. Constitutively activated STATs, especially 
STAT1, STAT3 and STAT5, have been found in a variety 
of human tumors and cancer cell lines, including blood 
malignancies and solid tumors[6-11]. STAT3 and STAT5 are 
considered as oncogenes, since they activate cyclin D1, 
c-Myc, and bcl-xl expression, which promotes cell-cycle 
progression, tumorigenic transformation, and concurrently 
inhibits apoptosis[6-11]. In contrast, STAT1 causes growth 
arrest, and promote apoptosis, and is therefore thought to 
be a potential tumor suppressor, even though its expression 
level may also increase in human neoplasias[12,13]. 
Therefore, the magnitude and specificity of STATs changes 
in various cancers underscores their potential values as 
molecular markers of tumor progression and their possible 
Objective: To  measure the expression pattern of STAT2 in cervical cancer initiation and 
progression in tissue sections from patients with cervicitis, dysplasia, and cervical cancer. 
Methods: Antibody against human STAT2 was confirmed by plasmids transient transfection 
and Western blot. Immunohistochemistry was used to detect STAT2 expression in the cervical 
biopsies by using the confirmed antibody against STAT2 as the primary antibody. Results: It was 
found that the overall rate of positive STAT2 expression in the cervicitis, dysplasia and cervical 
cancer groups were 38.5%, 69.4% and 76.9%, respectively. The STAT2 levels are significantly 
increased in premalignant dysplasia and cervical cancer, as compared to cervicitis (P< 0.05). 
Noticeably, STAT2 signals were mainly found in the cytoplasm, implying that STAT2 was not 
biologically active. Conclusions: These findings reveal an association between cervical cancer 
progression and augmented STAT2 expression. In conclusion, STAT2 increase appears to be an 
early detectable cellular event in cervical cancer development.
Liang Zeng et al./Asian Pacific Journal of Tropical Medicine (2012)738-742 739
roles in carcinogenesis itself. 
  Compared to other STATs, STAT2 is an uncharacteristic 
member in the STAT family. It is unique to the biological 
response to interferon (IFN)[14,15]. Studies using STAT2-
deficient cell lines and mice showed that STAT2 is necessary 
for the antiviral, apoptotic, and cell growth–inhibitory effects 
of type栺IFN[14,15]. Recently, studies with animal models 
have shown that STAT2-deficient mice have decreased 
tumor incidences to carcinogens, suggesting that STAT2 
plays a positive role in tumorigenesis[16]. But the detailed 
mechanism is not clear. So far, no data are yet available 
on the expression status of STAT2 in cancer initiation and 
progression. In this study, we analyzed STAT2 expression by 
immunohistochemistry (IHC) staining in biopsies of human 
cervicitis, cervical intra-epithelial neoplasia (CIN) stages栺-
栿, and cervical cancers in order to detect STAT2 expression 
pattern in cervical cancer development. 
2. Materials and methods
2.1. Patients
  Paraffin-embedded sections from a total of 176 cervical 
tissues, including 39 cervicitis, 72 CINs and 65 cervical 
invasive carcinomas from the Department of Pathology 
(Hunan Province Tumor Hospital, Hunan, China). The 
age ranged from 30 to 75 years old. Patients had received 
no cancer therapy before tissue collection. Informed 
consent was obtained from all patients. All diagnoses were 
made according to the published criteria of diagnostic 
histopathology of tumors. H&E-stained sections of cervical 
tissues were analyzed by a pathologist to confirm initial 
diagnosis, staging, and overall integrity of the tissue 
samples.
2.2. Cell culture, transfection, and Western blot
  The plasmids, pCMV-Myc and pCMV-Myc-STAT2, 
were a gift from ZG Dong (Hormel Institute, University of 
Minnesota, MN, USA). Human cervical adenocarcinoma cell 
line Caski and human embryonic kidney 293 (HEK293) were 
grown in Dulbecco minimal essential medium, containing 
antibiotics (100 U/mL penicillin, 100 毺g/mL streptomycin) 
supplemented with 10% heat-inactivated fetal calf serum 
(FCS), respectively. HEK293 cells were transfected with 
pCMV-Myc-mock or pCMV-Myc-STAT2 using Attractene 
transfection reagent (QIAGEN, Hilden, Germany) following 
the manufacturer’s suggested protocol. The transfected 
cells were cultured for 36 hours and proteins were extracted 
by using Nonidet P-40 cell lysis buffer (50 mmol/L Tris-
HCl, pH 8.0; 150 mmol/L NaCl; 0.5% Nonidet P-40; and 
protease-inhibitor cocktail). 30 毺g of total protein was 
resolved on 10% SDS-PAGE and were transferred to 
polyvinylidene difluoride membranes. The membranes 
were blocked with 5% nonfat dry milk in TBS (50 mM Tris, 
150mM NaCl) at room temperature for 1 hour, and were 
then incubated with rabbit anti-human STAT2 antibody 
(1:2 000, Santa Cruz Biotechnology, Santa Cruz, CA), or anti-
Myc antibody (1:2 000, Invitrogen, Carlsbad, CA) at 4 曟
overnight. Secondary horseradish peroxidase-conjugated 
antibody (Santa Cruz Biotechnology) was applied at a 
dilution of 1:2 000 for 2 hours at room temperature. Blots 
were developed by enhanced chemiluminescent detection 
(Amersham, Piscataway, NJ, USA) and exposed to X-ray film 
(Fuji).
2.3. Immunohistochemistry
  Immunohistochemistry was done on paraffin-embedded 
sections of cervical tissues. The tissue was deparaffinized by 
placing slides into three changes of xylene and rehydrated 
in a graded ethanol series. The rehydrated tissue samples 
were rinsed in water and subjected to antigen retrieval in 
citrate buffer (pH 6.0). Slides were treated with 3% H2O2 
for 5 minutes to reduce endogenous peroxidase activity 
and washed. STAT2 was detected using anti-STAT2 
antibody (Santa Cruz Biotechnology) at a 1:100 dilution and 
visualized using a commercial streptavidin-biotin immuno-
peroxidase complex kit (DAKO) following the manufacturer’s 
instructions. Negative control slides were incubated with 
blocking serum (Santa Cruz Biotechnology) under similar 
conditions. Counter staining of the nucleus was archived 
with hematoxylin. 
2.4. Evaluation of STAT2 expression
  Each IHC-stained slide was examined by two independent 
pathologists without knowledge of the clinical diagnosis 
and staging of patients. The percentage of STAT2 positive 
cervical epithelial cells was obtained by counting 1 000 
epithelial cells in 5-10 randomly selected fields. STAT2 
expression was graded according to the frequency and the 
signal intensity of positively stained cells. Grading criteria 
for frequency were: 3, >75% of epithelial cells with positive 
staining; 2, 50%-75% of epithelial cells with positive staining; 
1, 25%-50% of epithelial cells with positive staining; 0, <25% 
of cells with positive staining. Grading criteria for signal 
intensity were: 3, epithelial cells selectively stained brown; 
2, epithelial cells stained yellow; 1, epithelial cells stained 
faintly yellow, 0, lack of staining. A sum of above two scores 
smaller than 1 was defined as negative; that of 2-3 assigned 
+; that of 4-5 assigned ++, and that of more than 6 assigned 
+++. 
2.5. Statistics
  Two-tailed Fisher’s exact probability tests were used for 
comparison between categorical variables. The survival 
curve was plotted using the Kaplan-Meier estimator. 
Statistical difference in survival between groups of patients 
with positive or negative expression of STAT2 was compared 
by the log-rank. P<0.05 was considered statistically 
significant.
3. Results
  In order to confirm the specificity of antibody against 
human STAT2, plasmid of pCMV-Myc-STAT2 or pCMV-
Myc-mock was transfected into HEK293. 36 hours later, the 
HEK293 cell lysate as well as Caski lysate were analyzed 
by Western blot using antibody against STAT2 or Myc as 
the primary one, respectively. Figure 1 showed the positive 
signals at 113 kDa in Caski and HEK293 transfected with 
pCMV-Myc-STAT2, which demonstrated the specificity of 
antibody against human STAT2 (Figure 1).  
Liang Zeng et al./Asian Pacific Journal of Tropical Medicine (2012)738-742740
113 kDa
113 kDa
1                         2                          3
Myc
STAT2
Figure 1. Specificity of primary antibody against human STAT2 was 
confirmed by Western blot. 
pCMV-Myc-mock or pCMV-Myc-STAT2 was transfected into 
HER293 cells, respectively. 36 hours later, the cell lysates were 
collected and detected by Western blot with the anti-STAT2 antibody 
as the primary one. Caski cell lysate was also collected and detected 
by Immunoblot. Cell lysates were from 1.HEK293 transfected with 
pCMV-Myc-mock; 2. HEK293 transfected with pCMV-Myc-STAT2; 
3.Caski. The primary antibody was STAT2 antibody against an epitope 
corresponding to amino acids 662-851 mapping at the C-terminus of 
human STAT2.
  To determine whether STAT2 is relevant to human 
malignancy, we determined the expression levels of STAT2 
by immunohistochemistry in 176 uterine cervices, which 
were obtained from patients in different cervical pathological 
stages. Representative images of different STAT2 expression 
levels are shown in Figure 2. Noticeably, STAT2 signals were 
mainly found in the cytoplasm although few signals were in 
the nuclear (Figure 2). 
  The distribution of scores that reflect both the frequency 
of STAT2 positive cells and the intensity of staining among 
the pathological groups is shown in Table 1. The overall 
rate of positive STAT2 expression in the cervicitis, dysplasia 
and cervical cancer groups were 38.5%, 69.4% and 76.9%, 
respectively, representing increasing trend of STAT2 rates 
from cervicitis to dysplasia till cervical cancer. Two-tailed 
Fisher’s exact probability test showed that the increases in 
the overall rate of STAT2 detection in dysplasia biopsies and 
cervical cancer biopsies over the cervicitis biopsies were 
both highly statistically significant (P<0.01), whereas the 
small increase from the dysplasia tissues to the cancer group 
was not (P>0.05). 
Figure 2. Immunohistochemical staining of cervical tissue sections 
showed different expression levels of STAT2. 
Representative cervicitis (A), CIN 栺 (B), CIN 栻 (C), CIN 栿 (D) and 
cancer (E) specimens are shown (40伊 magnification). 
 
  We further performed statistical analysis for the expression 
of STAT2 in different stages of CIN (Table 2). It was found 
that CIN栺biopsies had a statistically higher STAT2 detection 
rate than cervicitis biopsies (P=0.001). However, there was 
no significant difference between the STAT2 detection rates 
of the CIN栺and CIN栻 biopsies, or those of CIN栻 and CIN 
栿 biopsies (P=0.090, 0.081, respectively). There was no 
significant difference in the expression of STAT2 between 
dysplasia of different pathological types (氈
2=2.429, P= 
0.161>0.05). Taken together, data presented in Table 1 and 
Table 2 suggested that, in most (about 70% patients), increase 
in STAT2 expression starts in the premalignant dysplasia 
and remains in cervical cancer.  
 To determine whether the STAT2 expression in the cervical 
cancer tissues correlates with patient 5-year post-diagnosis 
survival, a Fisher’s exact probability with the positive or 
negative STAT2 immunoreactivity in the cervical cancer 
patients was performed (Table 3). STAT2 immunoreactivity 
appeared to be higher in the survival group (62%); however, 
the difference was not statistically significant (P=0.150). 
Finally, 5-year post-diagnosis overall survival analysis 
was performed in these cervical cancer patients (15 
Table 1  
Expression of STAT2 in cervicitis, displaysia and carcinoma tissues (n=176).
Group No of cases Negative Weak Moderate Strong Total positive
Cervicitis 39 24(61.5%)   8(20.5%)   6(15.4%) 1(2.6%) 15(38.5%)
Dysplasia 72 22(30.6%) 34(47.2%) 15(20.8%) 1(1.4%) 50(69.4%)
Cancer 65 15(23.1%) 34(52.3%) 15(23.1%) 1(1.5%) 50(76.9%)
Table 2  
Expression of STAT2 in displaysia stages, CIN 栺, 栻,  栿.
Group No of cases Negative Weak Moderate Strong Total positive
Cervicitis 39  24(61.5%)   8(20.5%)   6(15.4%)       1(2.6%) 15(38.5%)
CIN栺 36    8(22.2%) 18(50.0%) 10(27.8%)       0(0.0%) 28(77.8%)
CIN 栻 10 3(30.0%)   3(30.0%) 3(30.0%)         1(10.0%)   7(70.0%)
CIN  栿 26  10(38.5%) 13(50.0%) 3(11.5%)       0(0.0%) 16(61.5%)
Table 3  
Univariate analysis of clinicopathological variables for survival in 65 cervical cancer patients.
STAT2 immunoreactivity
5-year post-diagnosis overall survival
+ -
Positive (n=50) 31(62%) 19(38%)
Negative(n=15)   6(40%)   9(60%)
Statistical analysis: Fisher’s exact probability test. +, survival; -, death.
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STAT2-negative, 50 STAT2-positive, comprising any 
positive staining) using the Kaplan-Meier method (Figure 
3). The median survival time of STAT2-positive patients 
was 44.3 months, compared with 33.8 months for STAT2-
negative patients. Nevertheless, this difference was still not 
statistically significant (P=0.10) (Figure 3), possibly due to 
relatively small number of patients in the STAT2 negative 
biopsies. However, it is not clear if STAT2 expression plays a 
role in patient survival.
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Figure 3.  Kaplan-Meier survival estimates of the overall probability 
of post-diagnosis 5-year survival stratified by STAT2 expression 
determined from immunohistochemical staining, in patients with 
cervical cancer. 
Group of STAT2 negative: black solid line; group of STAT2 positive, 
black dashed line.
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Figure  4.  STAT2 expression was higher in cervical adenocarcinoma 
than normal cervical tissues by searching www.oncomine.com. 
0: normal control group; 1: cervical adenocarcinoma; 7 and 5: number 
of samples.
4. Discussion 
  In the present study, we performed analysis of STAT2 
expression for 176 cervical biopsies with different 
pathological stages using immunohistochemistry. The 
specificity of primary antibody against STAT2 was confirmed 
by Western blot in Caski cell line and HEK293 transiently 
transcfeted with pCMV-Myc-STAT2. We found significantly 
increased STAT2 detection rates in cervical displaysia 
biopsies and cervical cancer biopsies, as compared to 
cervicitis biopsies. However, the STAT2 detection rates 
were similar among biopsies of different displaysia stages, 
and between the displaysia biopsies and cancer biopsies. 
These results suggest that increased STAT2 expression 
frequently starts in a premalignant stage and remains in 
cancer. However, it is not clear if STAT2 expression plays a 
role in the development of cervical cancer. Further analyses 
with increased number of biopsies with increased statistical 
power will be helpful to address this question.
  Although to our knowledge there is no published full-
length literature directly evaluating STAT2 expression in 
the cervical tissue, at least several groups have indirectly 
corroborated our findings by including STAT2 on some 
custom chips in type I endometrial cancers as well as 
nasopharyngeal carcinoma[17,18]. From the Oncomine 
database (www.oncomine.com), we found that STAT2 
was more highly expressed in cervical adenocarcinoma 
compared to normal tissues (Figure 4). The increased STAT2 
expression in cervical cancer might be a result of long-term 
activation of the JAK-STAT pathway in response to HPV 
infection-stimulated production of IFNs.
  STATs serve as a link between the cell surface and the 
nucleus, and this requires their physical movement from 
the cytoplasm to the nucleus[19,20]. Therefore, intra-nuclear 
staining of tumor cells was considered to indicate the 
presence of constitutively activated STATs[21]. However, 
the present data show that STAT2 was distributed in the 
cytoplasm of cervical dysplastic and cancerous epithelial 
cells, which implies that although STAT2 could be up-
regulated in dysplastic and cancerous epithelial cells, but 
is not biologically active. Consistent with this hypothesis, 
functionally inactive STAT2 has been detected in prostate 
cancer[21].
  The IFN system is a crucial component of the innate and 
adaptive immune response to virus infection. HPV infection 
is connected to 95 percent of all cervical cancer cases 
worldwide. Furthermore, HPV induces endogenous IFN 
expression resulting in STAT2 expression. In counterdefence, 
however, HPV has developed mechanisms to strand the 
STAT2 protein in the cytoplasm, suggesting that HPV has 
strategies to block STAT2 activity, resulting in avoiding 
innate immunity and adaptive immunity[22-24]. Therefore, 
in HPV infected cervical tissues, although STAT2 is highly 
expressed, it is retarded in cytoplasm, resulting in loss of its 
activity. Hence, the ability of the HPV to block IFN signaling 
may be important and necessary for the development 
of papilloma-virus-derived cancers[22-24]. In summary, 
whatever model accounts for the increased expression 
of STAT2, it is unlikely that the simple up-regulation of 
STAT2 expression results in their activation and nuclear 
accumulation.
  In contrast with our findings, Clifford found a significant 
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decrease in expression of STAT2 in 76% of skin squamous 
cell carcinoma (SCC)[25]. In order to explore the role of STAT2 
in skin carcinogenesis, Clifford et al. programmatically 
examined the expression of IFN-stimulated gene factor 
3 (ISGF-3) proteins (including STAT 1毩/毬, STAT2, and 
p48), which are important mediators of IFN-毩 signaling, in 
skin premalignancy and SCC. They observed a significant 
decrease in expression of one or more ISGF-3 proteins 
in SCC patients. Furthermore, they found that an IFN-
毩 sensitive skin squamous cell line forced expression 
of a dominant negative-acting STAT2 (dnSTAT2) showed 
diminished antigrowth effects with IFN-毩 stimulation via 
suppressing the up-regulation of several IFN-毩-inducible 
genes[26]. These data have led to the hypothesis that the 
suppressed expression of STAT2 resulting in consequent 
reduction in responsiveness to endogenous IFN likely are an 
early event in skin carcinogenesis. In all, combined with our 
findings, it was supposed that blocking STAT2 activity might 
be a molecular event in carcinogenesis.
  In conclusion, we report an increased STAT2 detection 
rate in premalignant cervical displaysia biopsies as well as 
cervical cancer biopsies, as compared to cervicitis biopsies. 
It remains to be determined if STAT2 expression facilitates 
or inhibits cervical cancer development.
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